title: Mouse motor nerve terminal immunoreactivity to synaptotagmin II during sustained quantal transmitter release.
abstract: An antibody directed against the lumenal NH2-terminus of synaptotagmin II was used to examine the distribution of this vesicular protein either after spontaneous acetylcholine release or after sustained release induced by La3+ or alpha-latrotoxin, in conditions that prevent endocytosis. The detection of the epitope was examined in the presence or absence of Triton X-100. We show that, in resting conditions of transmitter release, permeabilization of nerve terminal membranes is required for obvious detection of synaptotagmin Ii immunoreactivity whereas during sustained rates of quantal release, permeabilization is not necessary. These data indicate that, in the latter conditions, synaptotagmin II is incorporated into the terminal axolemma and its intravesicular domain exposed at the extracellular nerve terminal surface.
authors.affiliation: Laboratoire de Neurobiologie Cellulaire et Moléculaire, CNRS, Gif-sur-Yvette, France.
authors.forename: D
authors.initials: D
authors.lastname: Angaut-Petit
authors.forename: P
authors.initials: P
authors.lastname: Juzans
authors.forename: J
authors.initials: J
authors.lastname: Molgó
authors.forename: L
authors.initials: L
authors.lastname: Faille
authors.forename: M J
authors.initials: MJ
authors.lastname: Seagar
authors.forename: M
authors.initials: M
authors.lastname: Takahashi
authors.forename: Y
authors.initials: Y
authors.lastname: Shoji-Kasai
mesh_terms: D000109:Acetylcholine / Q000378:metabolism; D000818:Animals; D000939:Epitopes / Q000276:immunology; D005260:Female; D007074:Immunoglobulin G / Q000096:biosynthesis / Q000276:immunology; D066298:In Vitro Techniques; D007811:Lanthanum / Q000494:pharmacology; D008565:Membrane Proteins / Q000276:immunology / Q000378:metabolism*; D051379:Mice; D008856:Microscopy, Fluorescence; D009046:Motor Neurons / Q000378:metabolism*; D018482:Muscle, Skeletal / Q000187:drug effects / Q000294:innervation / Q000378:metabolism; D009411:Nerve Endings / Q000378:metabolism*; D009419:Nerve Tissue Proteins / Q000276:immunology / Q000378:metabolism*; D009469:Neuromuscular Junction / Q000187:drug effects / Q000378:metabolism; D018377:Neurotransmitter Agents / Q000378:metabolism*; D013111:Spider Venoms / Q000494:pharmacology; D013572:Synaptic Vesicles / Q000187:drug effects / Q000378:metabolism; D050861:Synaptotagmin II
chemical_list: D000939:Epitopes; D007074:Immunoglobulin G; D008565:Membrane Proteins; D009419:Nerve Tissue Proteins; D018377:Neurotransmitter Agents; D013111:Spider Venoms; D050861:Synaptotagmin II; C494263:Syt2 protein, mouse; C020763:alpha-latrotoxin; D007811:Lanthanum; D000109:Acetylcholine